Search research articles
Contact Us
Filters
Showing results (1-10 of 64) with videos related to
Page
of 7
Sort By:
Neurology(R) Neuroimmunology & Neuroinflammation
|
October 11, 2019
Pembrolizumab as a treatment for PML? Waiting for Godot
Renaud A Du Pasquier
Current Opinion in Neurology
|
May 6, 2010
A promenade along the stream of demyelination
Renaud A Du Pasquier
Antiviral Therapy
|
March 15, 2013
A light in the cognitive fog?
Matthias Cavassini, Renaud A Du Pasquier
Current Opinion in Neurology
|
May 6, 2010
Demyelination as a complication of new immunomodulatory treatments
Andreas P Lysandropoulos, Renaud A Du Pasquier
Journal of Neurovirology
|
April 24, 2003
Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial?
Renaud A Du Pasquier, Igor J Koralnik
Neurology. Clinical Practice
|
February 15, 2018
Posterior spinal cord infarctions due to neurosyphilis
Olivier Bill, Renaud A Du Pasquier, Patrik Michel
Neurology
|
August 28, 2013
Author Response
Renaud A Du Pasquier, Mathieu Canales, Myriam Schluep
CNS Drugs
|
April 12, 2014
Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis
Renaud A Du Pasquier, Daniel D Pinschewer, Doron Merkler
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
July 4, 2012
MOBP-specific cellular immune responses are weaker than MOG-specific cellular immune responses in patients with multiple sclerosis and healthy subjects
Samantha Jilek, Myriam Schluep, Giuseppe Pantaleo, et al.
Cellular and Molecular Life Sciences : CMLS
|
April 25, 2012
Type I IFN-mediated regulation of IL-1 production in inflammatory disorders
Kristina Ludigs, Valeriy Parfenov, Renaud A Du Pasquier, et al.
Page
of 7
Search research articles
Search
Showing results (1-10 of 64) with videos related to
Sort By:
Page
of 7
Neurology(R) Neuroimmunology & Neuroinflammation
|
October 11, 2019
Pembrolizumab as a treatment for PML? Waiting for Godot
Renaud A Du Pasquier
Current Opinion in Neurology
|
May 6, 2010
A promenade along the stream of demyelination
Renaud A Du Pasquier
Antiviral Therapy
|
March 15, 2013
A light in the cognitive fog?
Matthias Cavassini, Renaud A Du Pasquier
Current Opinion in Neurology
|
May 6, 2010
Demyelination as a complication of new immunomodulatory treatments
Andreas P Lysandropoulos, Renaud A Du Pasquier
Journal of Neurovirology
|
April 24, 2003
Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial?
Renaud A Du Pasquier, Igor J Koralnik
Neurology. Clinical Practice
|
February 15, 2018
Posterior spinal cord infarctions due to neurosyphilis
Olivier Bill, Renaud A Du Pasquier, Patrik Michel
Neurology
|
August 28, 2013
Author Response
Renaud A Du Pasquier, Mathieu Canales, Myriam Schluep
CNS Drugs
|
April 12, 2014
Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis
Renaud A Du Pasquier, Daniel D Pinschewer, Doron Merkler
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
July 4, 2012
MOBP-specific cellular immune responses are weaker than MOG-specific cellular immune responses in patients with multiple sclerosis and healthy subjects
Samantha Jilek, Myriam Schluep, Giuseppe Pantaleo, et al.
Cellular and Molecular Life Sciences : CMLS
|
April 25, 2012
Type I IFN-mediated regulation of IL-1 production in inflammatory disorders
Kristina Ludigs, Valeriy Parfenov, Renaud A Du Pasquier, et al.
Page
of 7